Results 101 to 110 of about 22,180 (202)

Clozapine‐induced diarrhea: A case report and mechanistic overview

Psychiatry and Clinical Neurosciences Reports, Volume 5, Issue 2, June 2026.
Abstract Background Clozapine is an atypical antipsychotic that is highly effective in managing treatment‐resistant schizophrenia. However, its use is associated with a wide range of adverse effects, including agranulocytosis, seizures, sedation, and gastrointestinal issues such as constipation, and less commonly, diarrhea. While constipation is a well‐
Shahab Dastmardi, Soha Namazi
wiley   +1 more source

Physiologically based pharmacokinetic modeling to predict the effect of risperidone on aripiprazole pharmacokinetics in subjects with different CYP2D6 genotypes and individuals with hepatic impairment

Therapeutic Advances in Drug Safety
Background: Aripiprazole and risperidone, widely used atypical antipsychotics, are commonly adjunctively prescribed in clinical practice. When aripiprazole was combined with risperidone, the genotype of drug-metabolizing enzymes and liver impairment may ...
Fan Mou, Zhiwei Huang, Yu Cheng, Xue Zhao, Xiujia Sun, Huafang Li, Shunying Yu   +6 more
doaj   +1 more source

Pediatric catatonia: A case report and review of the management

Psychiatry and Clinical Neurosciences Reports, Volume 5, Issue 2, June 2026.
Abstract Background Catatonia is when someone does not respond to stimuli or their environment whilst awake. Catatonia can present in a variety of ways, including a change in movement, speech, and behavior. There is limited research on the causes and management of catatonia in an adult population and even more so in the pediatric population.
Alison Thornton, Russell Birkett
wiley   +1 more source

Review of depot aripiprazole for schizophrenia

Patient Preference and Adherence, 2013
Farha Bilal Motiwala, Kim Stasia Siscoe, Rif S El-Mallakh Mood Disorders Research Program, Department of Psychiatry and Behavioral Sciences, University of Louisville School of Medicine, Louisville, KY, USA Abstract: Improving outcomes in schizophrenia ...
Motiwala FB, Siscoe KS, El-Mallakh RS
doaj  

Clozapine for treatment‐resistant schizophrenia with epilepsy: A case report

Psychiatry and Clinical Neurosciences Reports, Volume 5, Issue 2, June 2026.
Clozapine (CLOZ) is often avoided in treatment‐resistant schizophrenia with comorbid epilepsy due to seizure risks. We report a successful case managed through a cautious CLOZ titration guided by multimodal monitoring, including clinical scales and blood tests such as C‐reactive protein (CRP), CLOZ levels, and anti‐seizure medication (ASM) levels ...
Toru Horinouchi, Mayusa Mito, Toshiyuki Ishikawa, Yuichi Nakamura, Shuhei Ishikawa, Naoki Hashimoto   +5 more
wiley   +1 more source

Efficacy and safety of 2–4 mg brexpiprazole in the management of schizophrenia: A systematic review and meta‐analysis

Psychiatry and Clinical Neurosciences Reports, Volume 5, Issue 2, June 2026.
This graphical summary illustrates the efficacy and safety of brexpiprazole (2–4 mg) in patients with schizophrenia. The meta‐analysis demonstrates significant improvement in clinical outcomes, with reductions in Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression ‐ Severity scale (CGI‐S) scores, indicating better symptom ...
Sher Bano, Aashan Ahmad, Abdul Haseeb Mohammed, Ismailova Rushana Nurbekovna, Saja Saad, Noor Fatima, Muhammad Bilal Akbar, Zainab Salahuddin, Sadikun Nabi, Mohammad Mustafa Ababneh, Laiba Ajmal, Sidra Hariss, Hiba Manaf, Farah Saleh, Raouf Khan   +14 more
wiley   +1 more source

The importance of longitudinal evaluation using DAT‐SPECT in organophosphate‐induced toxic parkinsonism

Psychiatry and Clinical Neurosciences Reports, Volume 5, Issue 2, June 2026.
We performed longitudinal evaluation using magnetic resonance imaging (MRI) and dopamine transporter single‐photon emission computed tomography (DAT‐SPECT) in a case of organophosphate‐induced toxic parkinsonism. Fluid‐attenuated inversion recovery (FLAIR) images showed bilateral striatal hyperintensity in the acute phase, followed by reduction of ...
Shuhei Nakao, Yoichiro Kogoh, Hideki Funahashi, Yusei Yanoma, Minako Azuma, Yasushi Ishida, Yoji Hirano   +6 more
wiley   +1 more source

Low-dose aripiprazole for refractory burning mouth syndrome

Neuropsychiatric Disease and Treatment, 2016
Yojiro Umezaki,1 Miho Takenoshita,2 Akira Toyofuku2 1Psychosomatic Dentistry Clinic, Dental Hospital, 2Psychosomatic Dentistry, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan Abstract: We report a case
Umezaki Y, Takenoshita M, Toyofuku A
doaj  

Brivaracetam‐associated manic episode in a patient with bipolar disorder: A case report

Psychiatry and Clinical Neurosciences Reports, Volume 5, Issue 2, June 2026.
A patient with Bipolar I disorder developed manic symptoms following the initiation of brivaracetam for focal epilepsy. Although brivaracetam is generally considered to have favorable psychiatric tolerability, this case highlights a potential risk of mood destabilization in patients with underlying bipolar disorder.
Mihoko Kawai, Jun Miyata, Kousuke Kanemoto   +2 more
wiley   +1 more source

Machine‐learning classification of bipolar disorder incorporating wearable‐derived core body temperature and actigraphy‐derived sleep indices

Psychiatry and Clinical Neurosciences Reports, Volume 5, Issue 2, June 2026.
A machine‐learning approach combining wearable‐derived core body temperature (CBT) and actigraphy‐derived sleep indices showed preliminary discrimination between euthymic patients with bipolar disorder (BD) and normal controls. Total sleep time, wake time, and the wake time–CBT nadir phase difference were key contributors. Abstract Aim This study aimed
Kazuhiro Kurihara, Ayano Shiroma, Masaki Kamata, Naruyo Yoshimoto, Ayano Saso, Akiyoshi Shimura, Yukiko Imai, Tadashi Miyahara, Yoshikazu Takaesu   +8 more
wiley   +1 more source